Earl, H.M. et al. (2021) Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33(1), pp. 15-19. (doi: 10.1016/j.clon.2020.07.006) (PMID:32723485) (PMCID:PMC7382576)
Full text not currently available from Enlighten.
Abstract
No abstract available.
| Item Type: | Articles (Editorial) |
|---|---|
| Additional Information: | The PERSEPHONE trial was funded by NIHR HTA, NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (HTA/06/303/98). |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | MacPherson, Professor Iain |
| Authors: | Earl, H.M., Hiller, L., Dunn, J., Macpherson, I., Rea, D., Hughes-Davies, L., McAdam, K., Hall, P., Mansi, J., Wheatley, D., Abraham, J.E., Caldas, C., Gasson, S., O'Riordan, E., Wilcox, M., Miles, D., Cameron, D.A., and Wardley, A. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Clinical Oncology |
| Publisher: | Elsevier |
| ISSN: | 0936-6555 |
| ISSN (Online): | 1433-2981 |
| Published Online: | 25 July 2020 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details